INFERR-Iron infusion in haemodialysis study: INtravenous iron polymaltose for First Nations Australian patients with high FERRitin levels on haemodialysis—a protocol for a prospective open-label blinded endpoint randomised controlled trial ...

Abstract Background The effectiveness of erythropoiesis-stimulating agents, which are the main stay of managing anaemia of chronic kidney disease (CKD), is largely dependent on adequate body iron stores. The iron stores are determined by the levels of serum ferritin concentration and transferrin sat...

Full description

Bibliographic Details
Main Authors: Majoni, Sandawana William, Nelson, Jane, Germaine, Darren, Hoppo, Libby, Long, Stephanie, Divakaran, Shilpa, Turner, Brandon, Graham, Jessica, Cherian, Sajiv, Pawar, Basant, Rathnayake, Geetha, Heron, Bianca, Maple-Brown, Louise, Batey, Robert, Morris, Peter, Davies, Jane, Fernandes, David Kiran, Sundaram, Madhivanan, Abeyaratne, Asanga, Wong, Yun Hui Sheryl, Lawton, Paul D., Taylor, Sean, Barzi, Federica, Cass, Alan
Format: Article in Journal/Newspaper
Language:unknown
Published: figshare 2021
Subjects:
Online Access:https://dx.doi.org/10.6084/m9.figshare.c.5735684
https://springernature.figshare.com/collections/INFERR-Iron_infusion_in_haemodialysis_study_INtravenous_iron_polymaltose_for_First_Nations_Australian_patients_with_high_FERRitin_levels_on_haemodialysis_a_protocol_for_a_prospective_open-label_blinded_endpoint_randomised_controlled_trial/5735684
Description
Summary:Abstract Background The effectiveness of erythropoiesis-stimulating agents, which are the main stay of managing anaemia of chronic kidney disease (CKD), is largely dependent on adequate body iron stores. The iron stores are determined by the levels of serum ferritin concentration and transferrin saturation. These two surrogate markers of iron stores are used to guide iron replacement therapy. Most Aboriginal and/or Torres Islander Australians of the Northern Territory (herein respectfully referred to as First Nations Australians) with end-stage kidney disease have ferritin levels higher than current guideline recommendations for iron therapy. There is no clear evidence to guide safe and effective treatment with iron in these patients. We aim to assess the impact of intravenous iron treatment on all-cause death and hospitalisation with a principal diagnosis of all-cause infection in First Nations patients on haemodialysis with anaemia, high ferritin levels and low transferrin saturation Methods In a ...